Skip to main content

WORK PACKAGE 2

WP2: Phenotyping for personalized medicine

The goal of WORK PACKAGE 2 is to identify biomarkers and genetic/epigenetic markers for treatment effect and disease severity, as well as characterize and stratify early disease.

The work package will have professional responsibility for biobanking in the Clinical Trials Unit (CTU).

Work package leaders

Manager

Guro Løvik Goll, MD PhD

Deputy Chairman

Professor Benedicte Lie, Cand. Scient, PhD

More about the projects that are part of or associated with WORK PACKAGE 2:

WP1 - Optimized medical interventions

ARCTIC

Remission in patients with rheumatoid arthritis: a randomized controlled trial investigating the use of ultrasound in clinical follow-up

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

ARCTIC REWIND

Study on stepping up treatment for rheumatoid arthritis without loss of disease control.

Project Manager:
Espen A. Haavardsholm
WP2 - PPhenotyping for personalized medicine

BIKE

Biopsies of synovitis in the knee joint from patients with RA and OA

Project Manager:
Hilde Berner Hammer
WP2 - PPhenotyping for personalized medicine

BioTest

Experimental precision medicine

Project Manager:
Guro Løvik Goll
WP2 - PPhenotyping for personalized medicine

BOOGIE

Dynamics in BOne turnover markers in relation to Glucocorticoid treatment in patients with an Inflammatory joint disEase

Project Manager:
Birgitte Nellemann
WP2 - PPhenotyping for personalized medicine

MDR-RA

The Norwegian study for therapeutic drug monitoring

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

MERINO

Methotrexate in the treatment of erosive hand osteoarthritis

Project Manager:
Ida Bos-Haugen
WP6 - Dechiphering long-term outcomes

NOR-DMARD

The Norwegian register for antirheumatic drugs.

Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine

NOR DRUM

The Norwegian study for therapeutic drug monitoring

Project Manager:
Espen A. Haavardsholm
WP1 - Optimized medical interventions

NOR-SWITCH

Switching from originator to biosimilar in patients with inflammatory joint, intestinal or skin disease

Project Manager:
Tore K. Kvien
WP2 - PPhenotyping for personalized medicine

Nor-vaC

Immunological response to COVID-19 vaccine in patients on immunosuppressive therapy

Project Manager:
Guro Løvik Goll
WP2 - PPhenotyping for personalized medicine

RIMRA

Rheumatic immune-related adverse events in patients treated with immunotherapy

Project Manager:
Marte Schrumpf Heiberg
WP6 - Dechiphering long-term outcomes

SPACE

Early detection of spondyloarthritis

Project Manager:
Karen Minde Fagerli
WP2 - PPhenotyping for personalized medicine

START

Early diagnosis of newly occurring arthritis

Project Manager:
Silje Watterdal Syversen
WP2 - PPhenotyping for personalized medicine

ULTRARABIT

Longitudinal ultrasound study of patients with rheumatoid arthritis starting treatment with biological DMARDs

Project Manager:
Hilde Berner Hammer